Evidence appraisal forms are available for all study designs related to each domain of a clinical questionranging from randomized, controlled trials to case reports and qualitative studies in domains of treatment, diagnosis, and prognosis, to name a few. Based on the domain of the clinical question, then the study design to which the study applies, the user is guided to determine the aspects of the quality of the study as good quality, lesser quality, or lacking validity, reliability, or applicability. This quality level for each study represents the study design for the domain and the quality of the study, and is then easily translated into the body of evidence. On each appraisal form, the user is then able to see the context of each study by the domain of the question, the study design and evidence level, and the quality resulting from the appraisal.
P6-Pervasive developmental disorders: A shared knowledge synthesis
Joë lle M. André -Vert, MSc (Presenter) (Haute Autorité de Santé , La Plaine Saint Denis, France, Metropolitan); Muriel Dhenain, MD (Haute Autorité de Santé , La Plaine Saint Denis, France, Metropolitan) PRIMARY TRACK: Evidence generation and synthesis SECONDARY TRACK: Evidence sharing BACKGROUND (INTRODUCTION): Pervasive developmental disorders (PDD) gather a large diversity of clinical situations that require education, health, and social management. As a first step before guidelines development, National PDD policy commissioned the French National Authority for Health (HAS) to draft an evidence synthesis that would be shared among professionals and users' representatives. The purpose was to identify shared key messages on definition, epidemiology, functioning specificities, diagnostic, evaluation tools, and intervention description.
LEARNING OBJECTIVES (TRAINING GOALS):
1. Update current knowledge on pervasive developmental disorders. 2. Present a method to identify shared knowledge among professional and users' representatives. METHODS: Formal consensus method was adapted. A critical literature review was performed by searching medical and educational databases (MEDLINE, PsycINFO, CINAHL, Co-chrane Library, Base SantéPsy, SAPHIR, ERIC; 2000 -August 2009 English or French) . A steering committee drafted the evidence report based on clinical practice guidelines, systematic review, and, if further information needed, on clinical trials and extracted key message proposals. The evidence report was submitted to multidisciplinary peer reviewers and users' associations to complete the report and proposals. An independent rating panel graded each proposal, using a 9-point numerical scale. Evidence synthesis was drafted by the steering committee based on key messages, which were consensually judged conforming to scientific evidence (strong agreement if all marks were 7-9 after two rating tours and one interspersed meeting). RESULTS: 209/249 proposals received a strong agreement among professionals and users' representatives. No consensus was found on: French classification, exact prevalence of mental retardation associated with PDD, symptoms' evolution during adolescence and adulthood, possible evolution toward psychotic disorders.
DISCUSSION (CONCLUSION):
Whereas discussions among professionals and users' representatives frequently point out divergences, the formal consensus method helped them to find consensual key messages. These messages will be spread by initial and continuing education about PDD. This work will allow developing future guidelines on a shared knowledge. TARGET AUDIENCE(S): 1. Evidence synthesizer, developer of systematic reviews or meta-analyses 2. Guideline No clinical guidelines for Generalized Anxiety Disorder (GAD) have been developed in the United States. Early guideline development in psychiatric conditions outside the US has been hindered by lack of methodological quality and evidence, inadequate translation of evidence into recommendations, and no systematic updating. The GAD Guidelines Assessment (GAD-GA) Working Group was convened to identify recent credible clinical practice guidelines (CPGs), conduct guideline content syn-thesis and gap analysis, and provide information about critical issues involved with guideline development, use, and impact.
LEARNING OBJECTIVES (TRAINING GOALS):
1. Define the GAD-GA process to examine evidence in existing GAD guidelines. 2. Understand the process for recognizing guideline gaps. 3. Identify areas in need of future evidence generation to inform guideline development.
METHODS:
The GAD-GA process included: a MEDLINE search for existing GAD guidelines, limited to the English language, published in the previous 10 years; a systematic guideline assessment for quality, evidence strength and gaps; recommendations to inform future US guideline development. RESULTS: Thirteen GAD guidelines developed in the last decade were identified primarily from Canada, Europe, Asia, South Africa and the Pacific Rim. Eleven GAD guidelines, available in English, were evaluated and numerous evidence gaps were noted: 1) Limited information on duration of GAD treatment beyond initial 6-12 months. 2) No consideration of important GAD subpopulations (e.g., elderly, medically ill, children, and comorbid with other mental illnesses). 3) Lack of evidence for treatment failures beyond initial therapy. 4) Inadequate acknowledgment for role and duration of non-pharmacologic treatments (i.e., psychotherapy). wide range of disparate studies, particularly in areas where RCTs are lacking. Often, a narrative summary is used but this can be lengthy and may not easily allow understanding and interpretation of the totality of evidence.
LEARNING OBJECTIVES (TRAINING GOALS):
1. To encourage the use of graphical presentation in guideline development. 2. To describe the use of graphical summaries of data. METHODS: During the development of national guidelines, we wished to present evidence in a graphical format to complement the GRADE and evidence tables. RESULTS: We considered different graphical representations to summarize and present 69 studies included in an evidence review of ablative therapies in Barrett's esophagus. Initially, we considered the use of a linear representation (that is, a simple diagram showing which interventions were evaluated and, where appropriate, any comparisons). Although this provided a useful model for RCTs, it proved less applicable to the type of evidence considered in the ablative therapies guideline, primarily case series. We therefore used a Venn diagram approach, which allowed the representation of studies with or without a comparison, and the representation of studies with a combination of interventions.
DISCUSSION (CONCLUSION):
Graphical representation allowed us to present evidence in a simple and easily understandable way. Although we did not undertake a formal assessment, anecdotally, guideline group members found it extremely helpful in navigating the "evidence landscape." It was also useful for the technical team as an audit tool throughout.
Guideline developers could be more innovative in using graphical representation, especially when there is a wide range of evidence to be considered and statistical methods of summarizing the data are not possible. TARGET AUDIENCE(S): 1. Evidence synthesizer, developer of systematic reviews or meta-analyses. 2. Guideline developer. 3. Developer of guideline-based products.
